EUVIMEDEUVIMED entdecken
Open Access

Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease

Nyasha Lorraine Mapira iD, Roslyn Stella Thelingwani iD, Zedias Chikwambi iD, Patience Kuona iD, Collen Masimirembwa iD

Pharmacogenomics · 2023

DOI: 10.2217/pgs-2023-0045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Nyasha Lorraine Mapira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), 911 Boronia Township, Beatrice, Zimbabwe. Hauptthemen laut MEDLINE: Pharmacogenetics, Anemia, Sickle Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bill and Melinda Gates Foundation, European & Developing Countries Clinical Trials Partnership.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. Materials & methods: The authors conducted a cross-sectional study to determine the effect of CYP2D6 and UGT2B7 polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm® pharmacogenomics open array panel containing CYP2D6 and UGT genetic variants implicated in opioid response.

Results

The reduced function alleles CYP2D6*17 and *29 had high frequencies of 15.9% and 12.9%, respectively. UGT2B7 rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454).

Conclusion

This study demonstrated the role of UGT2B7 polymorphism in SCD patient pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsAnemia, Sickle CellHumansPain ManagementCytochrome P-450 CYP2D6Cross-Sectional StudiesZimbabweAnalgesics, OpioidPain

Stichwörter der Autor:innen

CYP2D6UGT2B7codeinegenetic variationmorphineopioidspharmacogenomicstramadol

Substanzen

Cytochrome P-450 CYP2D6Analgesics, Opioid

Autor:innen und Institutionen

  • Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), 911 Boronia Township, Beatrice, Zimbabwe.
  • Department of Biotechnology, Chinhoyi University of Technology, Private Bag 7724, Chinhoyi, Zimbabwe.
  • Child Adolescent Health Unit, Department of Primary Health Care, Faculty of Medicine & Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • Sydney Brenner Institute for Molecular Bioscience (SBIMB), University of the Witwatersrand, Johannesburg, Gauteng, 2000, South Africa.

ORCID-Profile: Nyasha Lorraine Mapira, Roslyn Stella Thelingwani, Zedias Chikwambi, Patience Kuona, Collen Masimirembwa

Förderung

  • NCI NIH HHS
  • Bill and Melinda Gates Foundation
  • European & Developing Countries Clinical Trials Partnership
  • National Institutes of Health

Zitieren

APA

Mapira, N. L., Thelingwani, R. S., Chikwambi, Z., Kuona, P., & Masimirembwa, C. (2023). Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0045

Vancouver

Mapira NL, Thelingwani RS, Chikwambi Z, Kuona P, Masimirembwa C. Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0045

BibTeX
@article{Mapira2023,
  author = {Mapira, Nyasha Lorraine and Thelingwani, Roslyn Stella and Chikwambi, Zedias and Kuona, Patience and Masimirembwa, Collen},
  title = {Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease},
  journal = {Pharmacogenomics},
  year = {2023},
  doi = {10.2217/pgs-2023-0045}
}
Kostenlos starten →